Drug intelligence / Profile preview

rivocibart

Development stage
Phase 3
Lead developer
Hengrui Therapeutics
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Subcutaneous
01

Overview

Rivocibart (development code SHR-1918) is a fully human monoclonal antibody that targets angiopoietin-like protein 3 (ANGPTL3). Developed by Jiangsu Hengrui Pharmaceuticals and its subsidiaries Beijing Shengdi Pharmaceutical (also known as Beijing Suncadia Pharmaceuticals), rivocibart is designed to treat lipid metabolism disorders. By inhibiting ANGPTL3, it disinhibits lipoprotein lipase (LPL) and endothelial lipase (EL), thereby promoting the clearance of triglycerides and low-density lipoprotein cholesterol (LDL-C) through an LDL receptor (LDL-R)-independent pathway. In November 2026, China's National Medical Products Administration (NMPA) approved rivocibart (under the brand name Aiqingda) as a Class 1 innovative drug for the treatment of homozygous familial hypercholesterolemia (HoFH) in adults and adolescents aged 12 and older. It is administered as a subcutaneous injection every four weeks. Rivocibart is also undergoing clinical evaluation for hypertriglyceridemia, hypercholesterolemia, and hyperlipidemia.

Brand names
Aiqingda
Other names
RuifexibartRuifexibart Injectionrivocibart injection
02

Targets

Beyond the preview

Go deeper on rivocibart.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on rivocibart.

Work on rivocibart? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call